Literature DB >> 9462738

Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch.

S Igarashi1, R Koide, T Shimohata, M Yamada, Y Hayashi, H Takano, H Date, M Oyake, T Sato, A Sato, S Egawa, T Ikeuchi, H Tanaka, R Nakano, K Tanaka, I Hozumi, T Inuzuka, H Takahashi, S Tsuji.   

Abstract

To elucidate the molecular mechanisms whereby expanded polyglutamine stretches elicit a gain of toxic function, we expressed full-length and truncated DRPLA (dentatorubral-pallidoluysian atrophy) cDNAs with or without expanded CAG repeats in COS-7 cells. We found that truncated DRPLA proteins containing an expanded polyglutamine stretch form filamentous peri- and intranuclear aggregates and undergo apoptosis. The apoptotic cell death was partially suppressed by the transglutaminase inhibitors cystamine and monodansyl cadaverine (but not putrescine), suggesting involvement of a transglutaminase reaction and providing a potential basis for the development of therapeutic measures for CAG-repeat expansion diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462738     DOI: 10.1038/ng0298-111

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  71 in total

Review 1.  Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.

Authors:  A Lunkes; Y Trottier; J Fagart; P Schultz; G Zeder-Lutz; D Moras; J L Mandel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  Polyglutamine pathogenesis.

Authors:  C A Ross; J D Wood; G Schilling; M F Peters; F C Nucifora; J K Cooper; A H Sharp; R L Margolis; D R Borchelt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Aggregation of truncated GST-HD exon 1 fusion proteins containing normal range and expanded glutamine repeats.

Authors:  B Hollenbach; E Scherzinger; K Schweiger; R Lurz; H Lehrach; E E Wanker
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 4.  Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.

Authors:  A S Hackam; J G Hodgson; R Singaraja; T Zhang; L Gan; C A Gutekunst; S M Hersch; M R Hayden
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 5.  The localization and interactions of huntingtin.

Authors:  A L Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

6.  Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin.

Authors:  S H Li; A L Cheng; H Li; X J Li
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

7.  Increased T-type Ca2+ channel activity as a determinant of cellular toxicity in neuronal cell lines expressing polyglutamine-expanded human androgen receptors.

Authors:  A Sculptoreanu; H Abramovici; A A Abdullah; A Bibikova; V Panet-Raymond; D Frankel; H M Schipper; L Pinsky; M A Trifiro
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

8.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 9.  The complex clinical and genetic classification of inherited ataxias. I. Dominant ataxias.

Authors:  S Di Donato
Journal:  Ital J Neurol Sci       Date:  1998-12

Review 10.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.